



Rexahn Pharmaceuticals, Inc.
Investor Relations Department
15245 Shady Grove Road, Suite
455
Rockville, MD 20850
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	2.27
Trade Time:	8:00 PM ET 09/19/17
Change:	-0.05 ↓ (2.155%)
Day Range	2.27 - 2.41
52-Week Range	1.27 - 7.10
Volume	199,794

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

09/11/17
[Rexahn Pharmaceuticals Presents Final Data from the Supinoxin™ Phase I Clinical study and New Preclinical Data on RX-3117 at the 2017 European Society for Medical Oncology \(ESMO\) Congress](#)

09/10/17
[Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Advanced Bladder Cancer at the 2017 European Society for Medical Oncology \(ESMO\) Congress](#)

09/06/17
[Rexahn Pharmaceuticals to Present at 19th Annual Rodman & Renshaw Global Investment Conference](#)

09/05/17
[Rexahn Pharmaceuticals to Present Updated Clinical and Preclinical Data at the 2017 European Society for Medical Oncology \(ESMO\) Congress](#)

09/01/17
[Rexahn Pharmaceuticals Announces Retirement of its Founder, Chang Ahn, Ph.D., from the Board of Directors](#)

Financials [\[View all \]](#)

[Fourth Quarter Financial Results](#)

02/24/17
[Annual Report \(10-K\)](#)

02/24/17
[Proxy Statement \(DEF 14A\)](#)

08/04/17
[Quarterly Report \(10-Q\)](#)

05/03/17
[Quarterly Report \(10-Q\)](#)

11/04/16
[Quarterly Report \(10-Q\)](#)